Iceland· IS-EU/1/11/731/007-012 & 014
Komboglyze
A metformin and saxagliptin product containing metforminum inn hýdróklóríð,saxagliptinum inn hýdróklóríð, registered in Iceland by AstraZeneca AB. The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Metformin and saxagliptin is registered in 12 of 19 countries.
Countries holding a registration under ATC A10BD10 (metformin and saxagliptin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Metformin and saxagliptin · ATC A10BD10
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Metforminum INN hýdróklóríð,Saxagliptinum INN hýdróklóríð
- Manufacturer
- AstraZeneca AB
- Country
- Iceland (IS)
- ATC code
- A10BD10
- ATC class
- Metformin and saxagliptin
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and saxagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and saxagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and saxagliptin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKOMBOGLYZEAstraZeneca AB, Södertälje
- United StatesSaxagliptin and MetforminMylan Pharmaceuticals Inc.
- SwitzerlandKombiglyze XR
- United KingdomKomboglyze 2.5mg/1000mg tabletsMawdsley-Brooks & Company Ltd
- SpainKOMBOGLYZE 2,5 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- CanadaKOMBOGLYZEASTRAZENECA CANADA INC
- IrelandKomboglyze 2.5 mg/1000 mg film-coated tabletsAstraZeneca AB
- FinlandKomboglyzeAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- France · Saxagliptine/Metformine Biogaran
- Liechtenstein · Komboglyze
- Malta · Saxagliptin/Metformin Pharos
- Norway · Komboglyze
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/147ea0fc-644f-4b3e-9551-f6bb39f58c03 GET /v1/drugs/147ea0fc-644f-4b3e-9551-f6bb39f58c03?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "A10BD10",
"marketed": false,
"strength": "2,5 mg/1000 mg",
"ma_number": "EU/1/11/731/007-012 & 014",
"substance": "Metforminum INN hýdróklóríð,Saxagliptinum INN hýdróklóríð",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "40871"
}See everything about metformin and saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.